[go: up one dir, main page]

WO2011066511A8 - Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof - Google Patents

Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof Download PDF

Info

Publication number
WO2011066511A8
WO2011066511A8 PCT/US2010/058230 US2010058230W WO2011066511A8 WO 2011066511 A8 WO2011066511 A8 WO 2011066511A8 US 2010058230 W US2010058230 W US 2010058230W WO 2011066511 A8 WO2011066511 A8 WO 2011066511A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mimetic
disclosed
amphipathic peptides
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/058230
Other languages
French (fr)
Other versions
WO2011066511A1 (en
Inventor
Alan T. Remaley
Amar A. Sethi
Dmitri Sviridov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baker Idi Heart & Diabetes Institute
US Department of Health and Human Services
Original Assignee
Baker Idi Heart & Diabetes Institute
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Idi Heart & Diabetes Institute, US Department of Health and Human Services filed Critical Baker Idi Heart & Diabetes Institute
Publication of WO2011066511A1 publication Critical patent/WO2011066511A1/en
Publication of WO2011066511A8 publication Critical patent/WO2011066511A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/36—Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed herein are apolipoprotein A-I mimetic peptides and peptide analogs that promote lipid efflux as well as have anti-inflammatory and anti-oxidant properties. Also disclosed herein are methods of using the disclosed peptides to treat or inhibit dyslipidemic or vascular disorders, such as methods to treat or prevent cardiovascular disease including atherosclerosis.
PCT/US2010/058230 2009-11-30 2010-11-29 Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof Ceased WO2011066511A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26529109P 2009-11-30 2009-11-30
US61/265,291 2009-11-30

Publications (2)

Publication Number Publication Date
WO2011066511A1 WO2011066511A1 (en) 2011-06-03
WO2011066511A8 true WO2011066511A8 (en) 2011-07-07

Family

ID=43416521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/058230 Ceased WO2011066511A1 (en) 2009-11-30 2010-11-29 Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2011066511A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022320A2 (en) * 2011-08-10 2013-02-14 Korea Advanced Institute Of Science And Technology Amphipathic peptide-lipase conjugate having advanced lipase activity and use thereof
WO2014025890A1 (en) * 2012-08-10 2014-02-13 University Of North Texas Health Science Center Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids
WO2015057583A1 (en) 2013-10-14 2015-04-23 The United States Of America, As Represented By The Secretary Treatment of chronic kidney disease with sahps
JP2017537904A (en) * 2014-11-21 2017-12-21 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ Synthetic peptide
CN110160991B (en) * 2019-06-18 2021-12-14 山东艾科达生物科技有限公司 Kit for measuring serum amyloid A content by nephelometry
CN111879949B (en) * 2020-08-05 2021-11-09 中国科学院昆明动物研究所 Application of substance for detecting or regulating lactoferrin expression quantity in preparation of medicine or kit for preventing and/or treating cardiovascular and cerebrovascular diseases
CN117580857A (en) * 2021-06-23 2024-02-20 美国政府(由卫生和人类服务部的部长所代表) APOC-II short mimetic peptides and methods of use
CN114940711B (en) * 2021-10-25 2023-05-12 中山大学 Apolipoprotein A-I mimetic peptides and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
EP0817874B1 (en) 1995-03-31 2003-05-28 Hyperion Catalysis International, Inc. Carbide nanofibrils and method of making same
US6156727A (en) 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
US6695920B1 (en) 2001-06-27 2004-02-24 Advanced Cardiovascular Systems, Inc. Mandrel for supporting a stent and a method of using the mandrel to coat a stent
US6527863B1 (en) 2001-06-29 2003-03-04 Advanced Cardiovascular Systems, Inc. Support device for a stent and a method of using the same to coat a stent
ATE469174T1 (en) 2004-10-15 2010-06-15 Us Gov Health & Human Serv AMPHIPATHIC HELIX-SHAPED MULTIDOMAIN PEPTIDES AND METHOD FOR USE THEREOF
US20080199398A1 (en) * 2006-06-16 2008-08-21 Brewer H Bryan Novel Peptides That Promote Lipid Efflux
WO2008094905A2 (en) * 2007-01-29 2008-08-07 Lipid Sciences, Inc. Encapsulated hdl mimetic peptides
JP5183349B2 (en) 2007-08-10 2013-04-17 キヤノン株式会社 Image reading apparatus, method for controlling the apparatus, and control program
US8936787B2 (en) * 2008-04-15 2015-01-20 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptides promoting lipid efflux

Also Published As

Publication number Publication date
WO2011066511A1 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
WO2011066511A8 (en) Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof
WO2010079431A3 (en) Compounds for the prevention and treatment of cardiovascular disease
MX2009008099A (en) Compounds for the prevention and treatment of cardiovascular diseases.
WO2012174487A3 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
WO2006045010A3 (en) Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
MX2010003074A (en) Use of hyperbranched polyesters and/or polyester amides for separating oil-in-water emulsions.
WO2013064900A8 (en) Oral immediate release formulations for substituted quinazolinones
UA109123C2 (en) PROBIOTIC COMPOSITION FOR THE APPLICATION IN THE TREATMENT OF INTESTINAL INFLAMMATION
EP4234698A3 (en) Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
WO2014096440A3 (en) Albumin composition for preventing and/or reducing formation of peptide fibrils
WO2009039337A3 (en) Inhibition of angiogenesis
WO2008156873A3 (en) Apoa-1 peptide mimetics
WO2012074980A3 (en) Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives
WO2014081702A3 (en) Synthetic linear apelin mimetics for the treatment of heart failure
WO2012065153A3 (en) Modified immune-modulating particles
WO2011091435A3 (en) Methods of treating liver disease
WO2012057492A3 (en) Rapamycin formulation using recombinant high-density lipoprotein including apolipoprotein a-i and a mutant thereof
WO2012075422A3 (en) Compositions and methods for treating amyloid plaque associated symptoms
WO2010129048A3 (en) Therapeutic compounds
WO2010000851A3 (en) Methods for modulating angiogenesis via dystrophin dp71
IL194585A0 (en) Phospholipid complexes of olive fruits or leaves extracts having improved bioavailability
WO2014039074A3 (en) Therapeutic compositions and related methods
WO2012078519A3 (en) 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
WO2011034659A3 (en) Advantageous mu-opiate receptor peptide compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10784427

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 10784427

Country of ref document: EP

Kind code of ref document: A1